For example, enzyme replacement therapy (ERT) has revolutionized the management of lysosomal storage diseases such as Gaucher’s disease, in which hydrolytic lysosomal β-glucocerebroside is administered to restore normal metabolic function, and Pompe disease, in which acid alpha-glucosidase (GAA) supplementation prevents glycogen accumulation in muscle tissues [32]. This evidence concerns the gene GAA and lysosomal storage disease.